Navigation Links
Fleming Pharmaceuticals Sells Ocean, Nephrocaps, Other Branded Products to Valeant
Date:1/11/2012

ST. LOUIS, Jan. 11, 2012 /PRNewswire/ -- Fleming Pharmaceuticals announced today that, effective December 22, 2011, it has sold its rights to its branded Ocean®, Nephrocaps®, Magonate® and ProBarimin QT® products to Valeant International (Barbados) SRL ("Valeant"). Valeant has appointed its affiliate, Valeant Pharmaceuticals North America LLC, to act as distributor of these products in the U.S.

Fleming also manufactures contract products for a broad customer base, including the federal government. Fleming has retained rights to manufacture and market its widely-known product ThyroShield, one of two FDA-approved potassium iodide medicines used in nuclear emergencies to block the thyroid gland from absorbing radioactive iodine to avoid thyroid cancer.  In addition, Fleming has retained its contract services business relating to the development, manufacture and testing for specialty pharmaceutical companies and its physical headquarters in St. Louis, Missouri.

Due to the excess capacity anticipated as a result of the sale of the announced four products, Fleming is now considering proposals from a number of pharma manufacturers for its Midwestern manufacturing capability. A private investment banking firm, Douglas Group, St. Louis, has been retained to facilitate consideration of potential merger or sale for the remaining Fleming operations.

For more information, visit www.valeant.com www.flemingpharma.com.


'/>"/>
SOURCE Fleming Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Media Statement on Nuclear Crisis in Japan: Fleming Pharmaceuticals Stepping Up Production of Nuclear Antidote
2. Fleming Pharmaceuticals Now Ready to Step Up Production of Nuclear Radiation Safeguard, ThyroShield®
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
(Date:5/3/2016)... major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market ... ... ... ... ...
(Date:5/3/2016)... 2016   BIOTRONIK will be exhibiting and ... the implant at the Heart Rhythm Society,s 37 th ... San Francisco . "Physicians and ... of patient care and satisfaction possible. Part of that ... every tomorrow," said Marlou Janssen , President, BIOTRONIK, ...
Breaking Medicine Technology:
(Date:5/6/2016)... , ... May 06, 2016 , ... ... and David Konur, CEO of Cardiovascular Institute of the South announced today that ... performing a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... performance in the industry’s gold standard KLAS Performance Report, Epic Consulting ... report assessed organizations that specialize in consulting services for electronic health record (EHR) ...
(Date:5/5/2016)... ... May 05, 2016 , ... Florida Hospital ... non-valvular atrial fibrillation (A-Fib) an alternative to long-term warfarin medication with the newly ... in April of 2015, Florida Hospital Pepin Heart Institute doctors successfully implanted the ...
(Date:5/5/2016)... , ... May 05, 2016 ... ... hands-on exercises, the Wharton Seminars for Business Journalists , led by ... of key business and economic issues.  This one-day program at the Wharton ...
(Date:5/5/2016)... ... May 05, 2016 , ... An essential tool for researching ... certain Canadian provinces is now available from the International Association of Industrial Accident ... The report, Workers’ Compensation Laws as of January 1, 2016, is ...
Breaking Medicine News(10 mins):